Paul A. Friedman's most recent trade in Madrigal Pharmaceuticals Inc was a trade of 1,400 Common Stock done at an average price of $350.0 . Disclosure was reported to the exchange on July 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 350.03 per share. | 18 Jul 2025 | 1,400 | 187,164 (1%) | 0% | 350.0 | 490,044 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 18 Jul 2025 | 1,400 | 188,564 (1%) | 0% | 9.5 | 13,230 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jul 2025 | 1,400 | 175,980 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 16 Jul 2025 | 26,176 | 213,340 (1%) | 0% | 9.4 | 247,363 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2025 | 26,176 | 180,080 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 354.65 per share. | 16 Jul 2025 | 6,851 | 194,148 (1%) | 0% | 354.6 | 2,429,697 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 355.61 per share. | 16 Jul 2025 | 5,784 | 188,364 (1%) | 0% | 355.6 | 2,056,860 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 350.17 per share. | 16 Jul 2025 | 5,541 | 207,799 (1%) | 0% | 350.2 | 1,940,275 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2025 | 2,700 | 177,380 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 16 Jul 2025 | 2,700 | 189,864 (1%) | 0% | 9.5 | 25,515 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 351.38 per share. | 16 Jul 2025 | 2,371 | 205,428 (1%) | 0% | 351.4 | 833,131 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 353.82 per share. | 16 Jul 2025 | 2,319 | 200,999 (1%) | 0% | 353.8 | 820,507 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 352.67 per share. | 16 Jul 2025 | 2,110 | 203,318 (1%) | 0% | 352.7 | 744,133 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 350.10 per share. | 16 Jul 2025 | 2,000 | 187,864 (1%) | 0% | 350.1 | 700,203 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 356.62 per share. | 16 Jul 2025 | 1,200 | 187,164 (1%) | 0% | 356.6 | 427,941 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 351.57 per share. | 16 Jul 2025 | 700 | 187,164 (1%) | 0% | 351.6 | 246,098 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 1,290 | 1,290 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 715 | 187,164 (1%) | 0% | 0 | Common Stock | |
| Prelude Therapeutics Inc | Paul A. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 38,000 | 38,000 | - | - | Director Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 1,105 | 1,105 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 714 | 186,449 (1%) | 0% | 0 | Common Stock | |
| Prelude Therapeutics Inc | Paul A. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 23,500 | 23,500 | - | - | Director Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 08 Apr 2024 | 26,270 | 212,005 (1%) | 0% | 9.5 | 248,252 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2024 | 26,270 | 206,256 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 244.86 per share. | 08 Apr 2024 | 5,663 | 201,171 (1%) | 0% | 244.9 | 1,386,646 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 246.96 per share. | 08 Apr 2024 | 5,028 | 194,065 (1%) | 0% | 247.0 | 1,241,710 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 248.59 per share. | 08 Apr 2024 | 4,866 | 185,735 (1%) | 0% | 248.6 | 1,209,642 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 244.12 per share. | 08 Apr 2024 | 3,730 | 206,834 (1%) | 0% | 244.1 | 910,566 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 247.76 per share. | 08 Apr 2024 | 3,464 | 190,601 (1%) | 0% | 247.8 | 858,241 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 245.71 per share. | 08 Apr 2024 | 2,078 | 199,093 (1%) | 0% | 245.7 | 510,591 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 242.95 per share. | 08 Apr 2024 | 1,441 | 210,564 (1%) | 0% | 243.0 | 350,094 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 03 Apr 2024 | 27,613 | 213,348 (1%) | 0% | 9.5 | 260,943 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 27,613 | 232,526 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 27,407 | 278,849 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 03 Apr 2024 | 27,407 | 213,142 (1%) | 0% | 9.4 | 258,996 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 245.34 per share. | 03 Apr 2024 | 18,806 | 187,556 (1%) | 0% | 245.3 | 4,613,823 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 18,710 | 260,139 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 03 Apr 2024 | 18,710 | 204,445 (1%) | 0% | 9.5 | 176,810 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 243.20 per share. | 03 Apr 2024 | 9,264 | 195,373 (1%) | 0% | 243.2 | 2,253,016 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 242.42 per share. | 03 Apr 2024 | 6,679 | 204,637 (1%) | 0% | 242.4 | 1,619,098 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 241.07 per share. | 03 Apr 2024 | 6,273 | 198,172 (1%) | 0% | 241.1 | 1,512,222 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 242.25 per share. | 03 Apr 2024 | 5,299 | 192,873 (1%) | 0% | 242.2 | 1,283,679 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 245.35 per share. | 03 Apr 2024 | 5,228 | 186,179 (1%) | 0% | 245.3 | 1,282,669 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 244.58 per share. | 03 Apr 2024 | 4,301 | 206,362 (1%) | 0% | 244.6 | 1,051,959 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 244.22 per share. | 03 Apr 2024 | 3,966 | 191,407 (1%) | 0% | 244.2 | 968,588 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 245.14 per share. | 03 Apr 2024 | 2,549 | 188,230 (1%) | 0% | 245.1 | 624,857 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 243.64 per share. | 03 Apr 2024 | 2,294 | 210,663 (1%) | 0% | 243.6 | 558,921 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 246.31 per share. | 03 Apr 2024 | 1,821 | 185,735 (1%) | 0% | 246.3 | 448,530 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 246.13 per share. | 03 Apr 2024 | 1,558 | 186,672 (1%) | 0% | 246.1 | 383,471 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 243.00 per share. | 03 Apr 2024 | 1,467 | 191,406 (1%) | 0% | 243.0 | 356,482 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 240.10 per share. | 03 Apr 2024 | 1,420 | 211,928 (1%) | 0% | 240.1 | 340,939 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 247.14 per share. | 03 Apr 2024 | 737 | 185,935 (1%) | 0% | 247.1 | 182,141 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 244.31 per share. | 03 Apr 2024 | 627 | 190,779 (1%) | 0% | 244.3 | 153,185 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 241.15 per share. | 03 Apr 2024 | 612 | 211,316 (1%) | 0% | 241.1 | 147,582 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 245.92 per share. | 03 Apr 2024 | 444 | 185,735 (1%) | 0% | 245.9 | 109,189 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 248.42 per share. | 03 Apr 2024 | 200 | 185,735 (1%) | 0% | 248.4 | 49,685 | Common Stock |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 242.00 per share. | 03 Apr 2024 | 185 | 212,957 (1%) | 0% | 242 | 44,770 | Common Stock |
| Prelude Therapeutics Inc | Paul A. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 23,500 | 23,500 | - | - | Director Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 26,668 | 26,668 (0%) | 0% | 0 | Common Stock | |
| Madrigal Pharmaceuticals Inc | Friedman A. Paul | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.92 per share. | 16 Jan 2023 | 2,254 | 20,001 (0%) | 0% | 243.9 | 549,796 | Common Stock |
| Prelude Therapeutics Inc | Paul A. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 34,300 | 34,300 | - | - | Director Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Prelude Therapeutics Inc | Paul A. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2021 | 23,344 | 23,344 | - | - | Director Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Paul A. Friedman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2021 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) |